Latest Period
Q1 2026
Security Snapshot
Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) Institutional Ownership
CUSIP: G7709Q104
13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026
Institutions Reporting
582
Shares (Excl. Options)
353,900,203
Price
$47.97
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Symbol
- RPRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 353,900,203
- Total 13F value
- $16,954,372,264
- Portfolio coverage rank
- 0.01%
- Share change
- -1,896,578
- Value change
- -$31,804,666
- Number of holders
- 582
- Shares outstanding
- 445,144,313
- SEC-reported price per share
- $54.48
- Insider filing price
- $54.48
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RPRX - Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share is tracked under CUSIP G7709Q104.
- 582 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 537 to 582 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $13,811,713,592 to $16,954,372,264.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 582 institutions filings for Q1 2026.
Security key
G7709Q104
Latest holder period
Q1 2026
13F holders
582
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
RPRX full holder history
Royalty Pharma plc SEC filings
Royalty Pharma plc company facts
Royalty Pharma plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G7709Q104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
RPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Legorreta Pablo G. | 20% | $3,372,819,557 | 103,112,796 | Legorreta G. Pablo | 16 May 2025 | |||
| MORGAN STANLEY | 9.2% | $1,394,427,274 | 38,907,011 | Morgan Stanley | 30 Jun 2025 | |||
| Capital International Investors | 7.7% | +16% | $1,265,287,125 | +$163,578,499 | 32,745,526 | +15% | Capital International Investors | 31 Dec 2025 |
| FMR LLC | 6.5% | -29% | $984,337,180 | -$400,247,331 | 27,900,714 | -29% | FMR LLC | 30 Sep 2025 |
| BlackRock, Inc. | 5.7% | $832,319,492 | 25,445,414 | BlackRock, Inc. | 31 Dec 2024 | |||
| Severgnini Achille G. | 4.8% | -15% | $1,164,070,183 | -$155,603,324 | 21,366,927 | -12% | Severgnini Achille G. | 12 Jun 2026 |
| GENERAL ATLANTIC, L.P. | 3.2% | $510,500,301 | 14,243,870 | General Atlantic, L.P. | 30 Jun 2025 | |||
| VANGUARD GROUP INC | 2.5% | $385,841,061 | 10,936,538 | The Vanguard Group | 30 Sep 2025 |
As of 31 Mar 2026, 582 institutional investors reported holding 353,900,203 shares of Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX). This represents 80% of the company’s total 445,144,313 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
56%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 9.8% | 43,571,633 | -21% | 0.13% | $2,090,131,406 |
| Capital International Investors | 7.9% | 35,005,736 | +13% | 0.39% | $1,679,225,156 |
| BlackRock, Inc. | 5.8% | 25,907,745 | -1.1% | 0.02% | $1,242,794,508 |
| FMR LLC | 5.7% | 25,152,242 | -4.3% | 0.06% | $1,206,553,066 |
| BAILLIE GIFFORD & CO | 3.6% | 16,155,677 | -5% | 0.79% | $774,987,825 |
| Swedbank AB | 2.6% | 11,586,693 | -3% | 0.58% | $555,813,663 |
| STATE STREET CORP | 2.5% | 10,989,851 | +3.2% | 0.02% | $527,183,152 |
| Capital World Investors | 1.8% | 8,036,714 | 0.05% | $385,521,171 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 7,869,632 | +1.9% | 0.02% | $376,524,510 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7% | 7,480,633 | -36% | 0.55% | $358,845,965 |
| Caledonia (Private) Investments Pty Ltd | 1.6% | 7,168,399 | -2.8% | 10% | $343,868,100 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1% | 4,531,886 | 0% | 0.01% | $217,394,571 |
| VICTORY CAPITAL MANAGEMENT INC | 0.87% | 3,853,808 | -25% | 0.12% | $184,867,170 |
| NORTHERN TRUST CORP | 0.86% | 3,808,735 | -4.9% | 0.02% | $182,705,016 |
| ROYAL LONDON ASSET MANAGEMENT LTD | 0.86% | 3,808,353 | +2019% | 0.38% | $182,686,693 |
| AQR CAPITAL MANAGEMENT LLC | 0.85% | 3,782,038 | +48% | 0.08% | $179,646,825 |
| Invesco Ltd. | 0.84% | 3,752,399 | +150% | 0.03% | $180,002,595 |
| Patient Capital Management, LLC | 0.82% | 3,643,716 | +9.3% | 6.5% | $174,789,053 |
| BANK OF AMERICA CORP /DE/ | 0.79% | 3,495,846 | +29% | 0.01% | $167,695,755 |
| Legal & General Group Plc | 0.76% | 3,362,872 | +8.9% | 0.04% | $161,316,967 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.7% | 3,095,766 | -0.74% | 0.03% | $148,503,894 |
| Amundi | 0.69% | 3,088,773 | +15% | 0.04% | $148,168,441 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.68% | 3,027,899 | +3.9% | 0.02% | $145,248,315 |
| CITADEL ADVISORS LLC | 0.6% | 2,681,069 | -49% | 0.09% | $128,610,880 |
| NEW SOUTH CAPITAL MANAGEMENT INC | 0.59% | 2,625,863 | -10% | 6% | $125,962,648 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
29
Latest
Q1 2026
Rows shown
1-25 of 29
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 353,900,203 | $16,954,372,264 | -$31,804,666 | $47.97 | 582 |
| 2025 Q4 | 357,672,122 | $13,811,713,592 | +$1,025,655,761 | $38.64 | 537 |
| 2025 Q3 | 327,857,254 | $11,565,432,295 | -$513,196,140 | $35.28 | 484 |
| 2025 Q2 | 342,210,637 | $12,333,363,729 | +$949,776,240 | $36.03 | 452 |
| 2025 Q1 | 317,255,108 | $9,879,343,045 | -$34,196,805 | $31.13 | 444 |
| 2024 Q4 | 320,707,173 | $8,183,523,072 | +$144,649,409 | $25.51 | 414 |
| 2024 Q3 | 312,434,792 | $8,832,030,084 | -$70,655,781 | $28.29 | 391 |
| 2024 Q2 | 316,171,106 | $8,334,967,211 | +$126,311,822 | $26.37 | 373 |
| 2024 Q1 | 311,994,207 | $9,469,625,864 | +$68,283,642 | $30.37 | 375 |
| 2023 Q4 | 310,848,061 | $8,731,929,890 | +$90,598,401 | $28.09 | 359 |
| 2023 Q3 | 300,556,312 | $8,159,558,450 | -$95,718,367 | $27.14 | 312 |
| 2023 Q2 | 302,776,880 | $9,312,865,143 | +$35,406,560 | $30.74 | 321 |
| 2023 Q1 | 301,740,017 | $10,870,806,631 | +$87,185,612 | $36.03 | 331 |
| 2022 Q4 | 299,214,570 | $11,818,548,636 | +$83,591,490 | $39.52 | 332 |
| 2022 Q3 | 298,186,963 | $11,983,269,244 | +$263,400,168 | $40.18 | 311 |
| 2022 Q2 | 291,545,338 | $12,256,604,812 | +$918,924,477 | $42.04 | 281 |
| 2022 Q1 | 270,383,631 | $10,536,275,796 | +$82,755,109 | $38.96 | 272 |
| 2021 Q4 | 268,200,640 | $10,687,984,091 | +$139,946,049 | $39.85 | 254 |
| 2021 Q3 | 265,367,304 | $9,590,727,932 | +$538,289,516 | $36.14 | 226 |
| 2021 Q2 | 250,410,928 | $10,263,954,175 | +$118,347,007 | $40.99 | 229 |
| 2021 Q1 | 246,400,511 | $10,747,503,399 | +$874,104,377 | $43.62 | 208 |
| 2020 Q4 | 226,132,987 | $11,317,812,164 | +$1,961,711,795 | $50.05 | 188 |
| 2020 Q3 | 155,310,287 | $6,522,638,173 | +$367,540,942 | $42.07 | 129 |
| 2020 Q2 | 146,093,806 | $7,034,558,503 | +$7,034,558,867 | $48.55 | 119 |
| 2020 Q1 | 15 | $1,000 | $66.67 | 1 |